Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1405-87-4
Molecular formula
C66H103N17O16S
Molecular weight
1422.7 g/mol
Drug class
Polypeptide antibiotictopical antibacterial agent
Mechanism of action
Inhibits bacterial cell-wall synthesis by preventing dephosphorylation and recycling of bactoprenol (undecaprenyl pyrophosphate), a lipid carrier required for transport of peptidoglycan precursors across the bacterial membrane.
Indications / reported uses
Topical treatment or prevention of infection in minor superficial skin wounds in authorised topical products
Ophthalmic formulations are used for selected superficial bacterial eye infections; route and combination product determine the indication. Topical and systemic uses are not interchangeable.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Bacitracin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bacitracin Permitted Daily Exposure (PDE) report (the Bacitracin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bacitracin Occupational Exposure Limit (OEL) report (the Bacitracin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.